收藏切换
Analysis of Hepatoprotective Drugs Utilization in Hepatology Outpatients in 119 Chinese Hospitals from 2016 to 2023
收藏切换
PDF
Yi WU1, Chen PAN1, Jing JIANG2, Yinchu CHEN3, Ying ZHAO1, Xiaozhu ZHOU1, Ranjia LIU1, Xiangli CUI1, *
Chinese Pharmaceutical Journal | 2024, 59(17) : 1658 - 1664
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(17): 1658-1664
Analysis of Hepatoprotective Drugs Utilization in Hepatology Outpatients in 119 Chinese Hospitals from 2016 to 2023
Full
Yi WU1, Chen PAN1, Jing JIANG2, Yinchu CHEN3, Ying ZHAO1, Xiaozhu ZHOU1, Ranjia LIU1, Xiangli CUI1, *
Affiliations
  • 1 Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
  • 2 Reproductive Medical Center, PLA Rocket Force Characteristic Medical Center, Beijing 100086, China
  • 3 Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
Published: 2024-09-08 doi: 10.11669/cpj.2024.17.014
Outline
收藏切换

OBJECTIVE To analyze the characteristics and drug cost of hepatoprotective drugs among outpatients in domestic hospitals and provide references for rational drug use. METHODS The outpatient prescription data of 119 hospitals in 9 cities from January 2016 to December 2023 was collected, and the clinical application of hepatoprotective drugs was analyzed. RESULTS A total of 8 635 977 prescriptions from 3 194 167 patients were obtained in this study. The most frequent diagnoses of hepatoprotective drugs were hepatitis B (7.59%), liver cirrhosis (5.11%) and non-alcoholic steatohepatitis (4.53%).98.15% of prescriptions for 1-2 hepatoprotective drugs are prescribed, and oral dosage forms account for 97.29%. The total drug cost of hepatoprotective drugs increased from 85.38 million yuan to 109.8 million yuan, and the average drug cost per time increased from 85.15 yuan to 95.52 yuan. The glycyrrhizin preparation was the most used regimen, and the polyene phosphatidylcholine+glycyrrhizin preparation was the most used regimen. CONCLUSIONS The aggregate costs on hepatoprotective medications appears a consistent annual increase, which brings economic burden to medical insurance. This study analyzes the trend of hepatoprotective drug costs in the past 8 years, which is of great significance to the drug management of patients with liver disease.

hepatitis B  /  hepatoprotective drugs  /  prescription analysis  /  drug cost  /  glycyrrhizin preparation
Yi WU, Chen PAN, Jing JIANG, Yinchu CHEN, Ying ZHAO, Xiaozhu ZHOU, Ranjia LIU, Xiangli CUI. Analysis of Hepatoprotective Drugs Utilization in Hepatology Outpatients in 119 Chinese Hospitals from 2016 to 2023[J]. Chinese Pharmaceutical Journal, 2024 , 59 (17) : 1658 -1664 . DOI: 10.11669/cpj.2024.17.014
Year 2024 volume 59 Issue 17
PDF
148
76
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.17.014
  • Receive Date:2024-01-26
  • Online Date:2025-12-30
  • Published:2024-09-08
Article Data
Affiliations
History
  • Received:2024-01-26
Funding
Affiliations
    1 Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
    2 Reproductive Medical Center, PLA Rocket Force Characteristic Medical Center, Beijing 100086, China
    3 Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.17.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT